
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) – Equities researchers at HC Wainwright reduced their FY2026 earnings estimates for Ocular Therapeutix in a research report issued on Tuesday, November 10th. HC Wainwright analyst Y. Chen now expects that the biopharmaceutical company will post earnings of ($1.62) per share for the year, down from their prior estimate of ($1.49). HC Wainwright has a “Buy” rating and a $28.00 price objective on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Ocular Therapeutix’s Q4 2026 earnings at ($0.46) EPS, Q1 2027 earnings at ($0.47) EPS, Q2 2027 earnings at ($0.47) EPS, Q3 2027 earnings at ($0.47) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.87) EPS.
Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.06). Ocular Therapeutix had a negative net margin of 648.64% and a negative return on equity of 59.95%. The business had revenue of $12.87 million during the quarter, compared to analyst estimates of $14.27 million. During the same period in the previous year, the business posted ($0.38) earnings per share. The firm’s revenue for the quarter was down 11.5% on a year-over-year basis.
Check Out Our Latest Stock Report on Ocular Therapeutix
Ocular Therapeutix Trading Down 1.1%
Shares of NASDAQ OCUL opened at $6.21 on Thursday. The firm has a fifty day moving average of $7.99 and a 200 day moving average of $8.91. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.12 and a quick ratio of 13.03. Ocular Therapeutix has a one year low of $5.99 and a one year high of $16.44.
Institutional Investors Weigh In On Ocular Therapeutix
Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Ocular Therapeutix in the second quarter valued at $190,278,000. Octagon Capital Advisors LP grew its stake in Ocular Therapeutix by 20.7% during the 1st quarter. Octagon Capital Advisors LP now owns 3,166,600 shares of the biopharmaceutical company’s stock worth $26,821,000 after purchasing an additional 543,000 shares in the last quarter. Marshall Wace LLP grew its stake in Ocular Therapeutix by 2,047.2% during the 3rd quarter. Marshall Wace LLP now owns 2,706,184 shares of the biopharmaceutical company’s stock worth $20,756,000 after purchasing an additional 2,580,151 shares in the last quarter. Deltec Asset Management LLC grew its stake in Ocular Therapeutix by 6.0% during the 3rd quarter. Deltec Asset Management LLC now owns 2,623,597 shares of the biopharmaceutical company’s stock worth $20,123,000 after purchasing an additional 147,400 shares in the last quarter. Finally, Commodore Capital LP purchased a new stake in Ocular Therapeutix during the 1st quarter worth about $21,810,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.
Insider Buying and Selling
In other news, insider Peter Kaiser sold 9,990 shares of the company’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $7.05, for a total value of $70,429.50. Following the transaction, the insider owned 254,388 shares of the company’s stock, valued at $1,793,435.40. This represents a 3.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Pravin Dugel sold 21,649 shares of the stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $10.77, for a total transaction of $233,159.73. Following the transaction, the insider directly owned 2,525,429 shares of the company’s stock, valued at approximately $27,198,870.33. This trade represents a 0.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 98,090 shares of company stock worth $787,920 over the last ninety days. 3.10% of the stock is currently owned by insiders.
More Ocular Therapeutix News
Investors following OCUL have been watching these news items:
- Positive Sentiment: A report highlights Ocular Therapeutix’s Phase 3 wet age-related macular degeneration (AMD) success, a potentially important clinical milestone. How Investors Are Reacting To Ocular Therapeutix (OCUL) Phase 3 Wet AMD Success
- Positive Sentiment: HC Wainwright raised its price target to $28 and retained a Buy rating; RBC Capital also kept its Buy rating, signaling continued analyst optimism. Ocular Therapeutix Stock Gets Price Target Increase from HC Wainwright RBC Capital Keeps Their Buy Rating
- Neutral Sentiment: Although the Phase 3 result is encouraging, another report notes that debate over OCUL’s valuation persists, which may temper enthusiasm about the clinical news. Ocular Therapeutix on Phase 3 AMD Win and Valuation Debate
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.
Read More
- Five stocks we like better than Ocular Therapeutix
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.
